Evaxion Biotech's lung cancer candidate ready for clinic

The next candidate developed by Evaxion Biotech is ready to enter the clinical phase. This candidate is a potential treatment for non-small cell lung cancer called EVX-03, the biotech firm reveals.
Evaxion Biotech CEO Lars Staal Wegner | Photo: Evaxion Biotech / PR
Evaxion Biotech CEO Lars Staal Wegner | Photo: Evaxion Biotech / PR
by christopher due karlsson, translated by catherine brett

Biotech firm Evaxion Biotech has decided to take its EVX-03 candidate, a potential treatment for non-small cell lung cancer (NSCLC), into the clinical phase.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading